Clinical Trial Update: Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial assessing safety and efficacy of burosumab (KRN23) in a patient with ENS and hypophosphatemic rickets has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatemic Rickets

Drugs mentioned

• Burosumab (burosumab)

Snippet

Sponsor: Redwood Dermatology Sciences | Conditions: Hypophosphatemia, Hypophosphatemic Rickets | Phase 3 | Status: COMPLETED